95 results on '"Kanao, Kent"'
Search Results
2. Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
3. Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report
4. Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report
5. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
6. Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
7. Efficacy of Abiraterone Acetate For High-Risk Hormone-Naïve Metastatic Prostate Cancer: A Comparison With Combined Androgen Blockade Therapy With Bicalutamide And Androgen Deprivation Therapy Alone
8. Safety of adjuvant gemcitabine plus cisplatin chemotherapy in a patient with bilateral ureteral cancer undergoing hemodialysis
9. Laparoendoscopic single‐site simple nephrectomy and reduced port procedure for inflammatory nonfunctioning kidney
10. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy
11. Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events
12. Dorsal Vein Complex Preserving Technique During Robot-Assisted Radical Prostatectomy
13. Prognostic significance of p16 expression in high‐grade prostate adenocarcinoma
14. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
15. Reduced port laparoscopic radical nephrectomy using an umbilical zigzag skin incision for renal cell carcinoma
16. A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy
17. Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment
18. Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report
19. Gemcitabine/Cisplatin therapy for an urothelial carcinoma patient undergoing hemodialysis: a case report
20. A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis‐assisted transurethral resection involving orally administered 5‐aminolevulinic acid
21. Increased infiltration of CCR4‐positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis
22. Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer
23. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer
24. Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells
25. Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy
26. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma
27. Impact of a novel biopsy instrument with a 25-mm side-notch needle on the detection of prostate cancer in transrectal biopsy
28. MP05-07 SHOULD GLEASON SCORE AT THE POSITIVE SURGICAL MARGIN APPEAR ON THE PATHOLOGY REPORT FOR ROBOT-ASSISTED RADICAL PROSTATECTOMY?
29. PD64-09 A LONG TERM COMPARISON OF PERSISTENCE OF DRUG THERAPY IN 1,970 PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
30. MP55-10 IMPORTANCE OF BACTERIAL STONE CULTURE AT TRANSURETHRAL LITHOTRIPSY: WHICH CASES REQUIRE BACTERIAL STONE CULTURE?
31. Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis
32. Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer
33. Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma
34. Abstract 4400: Targeting lactate dehydrogenase-A promotes docetaxel induced cytotoxicity predominantly in castration-resistant prostate cancer cells
35. Abstract 3961: Increased CCR4-positive regulatory T cells in biopsy specimen of poor prognosis prostate cancer
36. Utility of a novel biopsy instrument with long side-notch needle in the selection of patients for active surveillance.
37. Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer?
38. PD26-08 A LONG TERM COMPARISON OF ADHERENCE OF DRUG THERAPY IN 1,917 PATIENTS WITH OVERACTIVE BLADDER
39. MP43-14 UTILITY OF A NOVEL BIOPSY INSTRUMENT WITH LONG SIDE-NOTCH NEEDLE IN THE SELECTION OF PATIENTS FOR ACTIVE SURVEILLANCE
40. MP11-10 CLINICAL PHARMACOKINETICS OF BETA-LACTAM ANTIBIOTICS IN PROSTATE TISSUE, AND DOSING CONSIDERATIONS FOR PROSTATITIS BASED ON SITE-SPECIFIC PHARMACODYNAMICS
41. MP16-07 USEFULNESS OF INFLAMMATORY MARKER DYNAMICS ONE MONTH AFTER THE FIRST-LINE TARGETED THERAPY INITIATION FOR PFS PREDICTION IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA
42. MP67-11 THE IMPACT OF MODIFIED INTERNATIONAL METASTATIC RENAL CELL CARCINOMA DATABASE CONSORTIUM MODEL USING A TWO-STEP STRATIFICATION PROCESS
43. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model11Dr. Mizuno reports grants from The Japan Agency for Medical Research and Development (AMED), personal fees from Pfizer, grants and personal fees from Novartis, during the conduct of the study. Dr. Mikami reports grants from The Japan Agency for Medical Research and Development (AMED) during the conduct of the study. Dr. Oya reports grants from The Japan Agency for Medical Research and Development (AMED), grants and personal fees from Pfizer, grants and personal fees from Novartis, personal fees from Bayer, during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.
44. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma
45. Novel algorithm for management of acute epididymitis
46. External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study
47. Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
48. S&T-57 NOVEL TRU-CUT NEEDLE WITH 25 MM CUTTING LENGTH IMPROVES THE DETECTION RATE OF PROSTATE CANCER IN TRANSRECTAL PROSTATE BIOPSY
49. MP18-14 CAN SMALL LESIONS OF GLEASON 3+4 BE LEFT UNTREATED IN FOCAL THERAPY? ANALYSIS OF RADICAL PROSTATECTOMY SPECIMENS.
50. MP27-18 IMPACT OF MAXIMUM TUMOR DIAMETER ADJUSTED BY PRIMARY TUMOR LOCATION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA MANAGED BY RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.